Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has James Piercy's publication output changed over time?
ScholarIQpublication output · 2004–2025
Output grew0% over the shown period — from 1 works in 2004 to 1 in 2025.
1
1
1
2
2
2
1
1
20042008201220132016201720232025
What are the most-cited papers on James Piercy?
ScholarIQmost cited works
Real-world physician and patient behaviour across countries: Disease-Specific Programmes – a means to understand
Peter Anderson, M Benford, Nancy L. Harris, M Karavali, James Piercy
Current Medical Research and Opinion. 2008517 Citations
Immunogenicity and protective efficacy of influenza vaccination
C Hannoun, Francoise Megas, James Piercy
S114911520. 2004263 Citations
Trends in medication use in patients with type 2 diabetes mellitus: a long-term view of real-world treatment between 2000 and 2015
Victoria Higgins, James Piercy, Adam Roughley, Gary Milligan, Andrea Leith, James Siddall, M Benford
Diabetes Metabolic Syndrome and Obesity. 2016256 CitationsOPEN ACCESS
Evidence for validity of a national physician and patient-reported, cross-sectional survey in China and UK: the Disease Specific Programme
S.M. Babineaux, B. Curtis, Tim Holbrook, Gary Milligan, James Piercy
BMJ Open. 2016250 CitationsOPEN ACCESS
Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes
Mirko Sikirica, Alan Martin, Robert Wood, Andrea Leith, James Piercy, Victoria Higgins
Diabetes Metabolic Syndrome and Obesity. 2017220 CitationsOPEN ACCESS
Related on ScholarIQ
Adelphi Group (United Kingdom)
Institution
Real-world physician and patient behaviour across countries: Disease-Specific Programmes – a means to understand
Paper
Immunogenicity and protective efficacy of influenza vaccination
Paper
Trends in medication use in patients with type 2 diabetes mellitus: a long-term view of real-world treatment between 2000 and 2015
Paper
Evidence for validity of a national physician and patient-reported, cross-sectional survey in China and UK: the Disease Specific Programme
Paper
Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes
Paper